These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16355673)

  • 1. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism.
    Barker EN; Campbell S; Tebb AJ; Neiger R; Herrtage ME; Reid SW; Ramsey IK
    J Vet Intern Med; 2005; 19(6):810-5. PubMed ID: 16355673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
    Clemente M; De Andrés PJ; Arenas C; Melián C; Morales M; Pérez-Alenza MD
    Vet Rec; 2007 Dec; 161(24):805-9. PubMed ID: 18083978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.
    Helm JR; McLauchlan G; Boden LA; Frowde PE; Collings AJ; Tebb AJ; Elwood CM; Herrtage ME; Parkin TD; Ramsey IK
    J Vet Intern Med; 2011; 25(2):251-60. PubMed ID: 21352377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
    Reine NJ
    Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment.
    Arenas C; Melián C; Pérez-Alenza MD
    J Vet Intern Med; 2014; 28(2):473-80. PubMed ID: 24495125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old or new? A comparison of mitotane and trilostane for the management of hyperadrenocorticism.
    Griffies JD
    Compend Contin Educ Vet; 2013 May; 35(5):E3. PubMed ID: 23677783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog.
    Park SM; Kim KB; Song WJ; Youn HY
    Vet Med Sci; 2021 Jul; 7(4):1150-1153. PubMed ID: 33755348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.
    Aldridge C; Behrend EN; Kemppainen RJ; Lee-Fowler TM; Martin LG; Ward CR; Bruyette D; Pannu J; Gaillard P; Lee HP
    J Vet Intern Med; 2016 Sep; 30(5):1637-1641. PubMed ID: 27425787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.
    Nagata N; Kojima K; Yuki M
    J Vet Intern Med; 2017 Jan; 31(1):22-28. PubMed ID: 27906457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperadrenocorticism: treating dogs.
    Brown CG; Graves TK
    Compend Contin Educ Vet; 2007 Mar; 29(3):132-4, 136, 138 passim; quiz 144-5. PubMed ID: 17726933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of hyperadrenocorticism in the dog.
    Braddock JA
    Aust Vet J; 2003; 81(1-2):31-3. PubMed ID: 15084005
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
    Alenza DP; Arenas C; Lopez ML; Melian C
    J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
    Braddock JA; Church DB; Robertson ID; Watson AD
    Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.
    Reid LE; Behrend EN; Martin LG; Kemppainen RJ; Ward CR; Lurye JC; Donovan TC; Lee HP
    J Vet Intern Med; 2014; 28(2):443-50. PubMed ID: 24400747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane.
    Peterson ME; Kintzer PP
    Vet Clin North Am Small Anim Pract; 1997 Mar; 27(2):255-72. PubMed ID: 9076906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy.
    Witt AL; Neiger R
    Vet Rec; 2004 Mar; 154(13):399-400. PubMed ID: 15083974
    [No Abstract]   [Full Text] [Related]  

  • 17. Mitotane (o,p'-DDD) resistance in a dog with pituitary-dependent hyperadrenocorticism and phaeochromocytoma.
    Bennett PF; Norman EJ
    Aust Vet J; 1998 Feb; 76(2):101-3. PubMed ID: 9578778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
    Arenas C; Melián C; Pérez-Alenza MD
    J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
    Feldman EC; Nelson RW; Feldman MS; Farver TB
    J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urine protein content in dogs with pituitary-dependent hyperadrenocorticism.
    Hurley KJ; Vaden SL
    J Am Vet Med Assoc; 1998 Feb; 212(3):369-73. PubMed ID: 9470045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.